PURPOSE: The L1 cell adhesion molecule (L1CAM) is considered a valuable target for therapeutic intervention in different types of cancer. Recent studies have shown that anti-L1CAM radioimmunotherapy (RIT) with (67)Cu- and (177)Lu-labelled internalising monoclonal antibody (mAb) chCE7 was effective in the treatment of human ovarian cancer xenografts. In this study, we directly compared the therapeutic efficacy of anti-L1CAM RIT against human ovarian cancer under equitoxic conditions with the radiolanthanide (177)Lu and the potential alternative (161)Tb in an ovarian cancer therapy model. METHODS: Tb was produced by neutron bombardment of enriched (160)Gd targets. (161)Tb and (177)Lu were used for radiolabelling of DOTA-conjugated antibodies. The in vivo behaviour of the radioimmunoconjugates (RICs) was assessed in IGROV1 tumour-bearing nude mice using biodistribution experiments and SPECT/CT imaging. After ascertaining the maximal tolerated doses (MTD) the therapeutic impact of 50 % MTD of (177)Lu- and (161)Tb-DOTA-chCE7 was evaluated in groups of ten mice by monitoring the tumour size of subcutaneous IGROV1 tumours. RESULTS: The average number of DOTA ligands per antibody was 2.5 and maximum specific activities of 600 MBq/mg were achieved under identical radiolabelling conditions. RICs were stable in human plasma for at least 48 h. (177)Lu- and (161)Tb-DOTA-chCE7 showed high tumour uptake (37.8-39.0 %IA/g, 144 h p.i.) with low levels in off-target organs. SPECT/CT images confirmed the biodistribution data. (161)Tb-labelled chCE7 revealed a higher radiotoxicity in nude mice (MTD: 10 MBq) than the (177)Lu-labelled counterpart (MTD: 12 MBq). In a comparative therapy study with equitoxic doses, tumour growth inhibition was better by 82.6 % for the (161)Tb-DOTA-chCE7 than the (177)Lu-DOTA-chCE7 RIT. CONCLUSIONS: Our study is the first to show that anti-L1CAM (161)Tb RIT is more effective compared to (177)Lu RIT in ovarian cancer xenografts. These results suggest that (161)Tb is a promising candidate for future clinical applications in combination with internalising antibodies.
PURPOSE: The L1 cell adhesion molecule (L1CAM) is considered a valuable target for therapeutic intervention in different types of cancer. Recent studies have shown that anti-L1CAM radioimmunotherapy (RIT) with (67)Cu- and (177)Lu-labelled internalising monoclonal antibody (mAb) chCE7 was effective in the treatment of humanovarian cancer xenografts. In this study, we directly compared the therapeutic efficacy of anti-L1CAM RIT against humanovarian cancer under equitoxic conditions with the radiolanthanide (177)Lu and the potential alternative (161)Tb in an ovarian cancer therapy model. METHODS:Tb was produced by neutron bombardment of enriched (160)Gd targets. (161)Tb and (177)Lu were used for radiolabelling of DOTA-conjugated antibodies. The in vivo behaviour of the radioimmunoconjugates (RICs) was assessed in IGROV1 tumour-bearing nude mice using biodistribution experiments and SPECT/CT imaging. After ascertaining the maximal tolerated doses (MTD) the therapeutic impact of 50 % MTD of (177)Lu- and (161)Tb-DOTA-chCE7 was evaluated in groups of ten mice by monitoring the tumour size of subcutaneous IGROV1 tumours. RESULTS: The average number of DOTA ligands per antibody was 2.5 and maximum specific activities of 600 MBq/mg were achieved under identical radiolabelling conditions. RICs were stable in human plasma for at least 48 h. (177)Lu- and (161)Tb-DOTA-chCE7 showed high tumour uptake (37.8-39.0 %IA/g, 144 h p.i.) with low levels in off-target organs. SPECT/CT images confirmed the biodistribution data. (161)Tb-labelled chCE7 revealed a higher radiotoxicity in nude mice (MTD: 10 MBq) than the (177)Lu-labelled counterpart (MTD: 12 MBq). In a comparative therapy study with equitoxic doses, tumour growth inhibition was better by 82.6 % for the (161)Tb-DOTA-chCE7 than the (177)Lu-DOTA-chCE7 RIT. CONCLUSIONS: Our study is the first to show that anti-L1CAM (161)Tb RIT is more effective compared to (177)Lu RIT in ovarian cancer xenografts. These results suggest that (161)Tb is a promising candidate for future clinical applications in combination with internalising antibodies.
Authors: Jean-Pierre Pouget; Lore Santoro; Laure Raymond; Nicolas Chouin; Manuel Bardiès; Caroline Bascoul-Mollevi; Helena Huguet; David Azria; Pierre-Olivier Kotzki; Monique Pèlegrin; Eric Vivès; André Pèlegrin Journal: Radiat Res Date: 2008-08 Impact factor: 2.841
Authors: Paul Chen; Judy Wang; Kristin Hope; Liqing Jin; John Dick; Ross Cameron; Joseph Brandwein; Mark Minden; Raymond M Reilly Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057
Authors: Russell J Schilder; Michael W Sill; Roger B Lee; Tanya J Shaw; Mary K Senterman; Andres J Klein-Szanto; Zoe Miner; Barbara C Vanderhyden Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Cristina Müller; Christiaan Vermeulen; Karl Johnston; Ulli Köster; Raffaella Schmid; Andreas Türler; Nicholas P van der Meulen Journal: EJNMMI Res Date: 2016-04-23 Impact factor: 3.138
Authors: Stephanie Haller; Giovanni Pellegrini; Christiaan Vermeulen; Nicholas P van der Meulen; Ulli Köster; Peter Bernhardt; Roger Schibli; Cristina Müller Journal: EJNMMI Res Date: 2016-02-09 Impact factor: 3.138
Authors: Gregory W Severin; Lotte K Kristensen; Carsten H Nielsen; Jesper Fonslet; Andreas I Jensen; Anders F Frellsen; K M Jensen; Dennis R Elema; Helmut Maecke; Andreas Kjær; Karl Johnston; Ulli Köster Journal: Front Med (Lausanne) Date: 2017-07-12